RNAi is an evolutionarily conserved process of sequence-specific, post-transcriptional gene silencing. RNAi is initiated by dsRNA that is homologous in sequence to the silenced gene [1] [2] [3] . RNAi is a shared phenomenon with similar pathways in plants [4] , fungi [2] , protozoa [5] and animals [1] . It is commonly thought that the origin of RNAi has evolved from a natural defense mechanism against foreign dsDNA, which is a key intermediate in the life cycle of many viruses [6] .
In normal cellular activity RNAi is mediated by miRNA. miRNA are endogenous, noncoding RNA molecules of ~22 nucleotides [7] that are located in independent noncoding transcripts or in introns of protein-coding genes [8] . miRNA are either transcribed by RNA polymerase II and then processed into a size of approximately 70 kDa by a microprocessor complex (comprising Drosha and the microprocessor complex subunit DCGR8) [9] or are processed from short introns [10] . Most miRNAs are expressed in a tissue-specific and developmental stage-specific manner and are crucial for many cell processes such as cell maturation and division [8] . In 1998, Fire et al. found that the injection of dsRNA into Caenorhabditis elegans led to an efficient sequence-specific gene silencing [11] , proving that RNAi can be mediated by exogenous delivery of siRNA and not only by endogenous miRNA.
When siRNA is introduced into the cell it will interact and bind to the RNA-induced silencing complex (RISC) [12] . The RISC selectively retains the antisense siRNA strand (guide strand) and silences gene expression by degrading the complementary and corresponding mRNA strand [13] . The cleavage position on the mRNA is located between nucleotides 10 and 11 when counting from the 5´-end of the antisense strand [6] . The passenger strand will be cut by Argonute 2, one of the proteins within the RISC complex, and consequently removed from the RISC complex [13] . The selectivity of the strand loading into the RISC complex is based on differential thermodynamic stabilities at the terminus of the siRNA molecule [14] . The siRNA strand incorporated into RISC is recycled, thus repeatedly downregulating gene expression with only a small amount of siRNA. Another key feature of siRNA-mediated gene silencing is that the entire process occurs within the cytoplasm of the cell, thus circumventing the need for nuclear delivery and alleviating concerns over the direct modification of the host genome [15] .
RNAi is not necessarily dependent on exogenous siRNA. It was shown that 25-27 long oligonucleotides termed DICER substrates can be processed into siRNA by the DICER protein [16] , or alternatively RNAi can be accomplished using a DNA plasmid. The DNA plasmids can transcribe either RNA duplexes or hairpin RNAs [17] . Plasmids benefit from having stable expression and thus have a permanent effect on the transfected cells [18] . Additionally multiple siRNA molecules can be encoded on one plasmid thus enhancing RNAi activity [19] . The hurdles of employing DICER substrates and DNA templates in vivo are analogous to that of using exogenous siRNA and thus will not be addressed specifically in this report.
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Therapeutic potential of rNAi
Selective gene silencing has been sought after as a therapeutic method for many years. Early attempts at gene silencing, such as the antisense approach, were based on Watson-Crick base pairing interactions [20] . Using this strategy, all the mRNA can be silenced, and the silencing would be gene specific. Thus, antisense drugs were considered as a superior alternative to small molecule drugs for their sequence-specific approach. Although some compounds were sucsseful such as formiviresn [21] , which was the first antisense drug to be approved by the US FDA, it was the discovery of the siRNA pathway that accelerated the development of RNAi-based therapeutics. Although both antisense drugs and siRNA affect gene expression by mRNA degradation, siRNA has several advantages over antisense-based drugs. The main advantage is the amount of oligonucleotides that are needed to achieve gene silencing. The siRNA method requires significantly lower concentrations of oligonucleotides than antisense drugs and the gene inhibition effect lasts longer due to the catalytic nature of the mechanism [22] . In addition, siRNA molecules are relatively easy to synthesize and have a low cost production [23] .
The immune response
It is the role of the immune system to initiate, organize and control the immune response. In vertebrates the immune system is divided into two branches: innate and adaptive immunity. It is the task of the innate immune system to serve as the first line of defense by detecting invading pathogens via evolutionary conserved receptors; the detection is followed by destruction and clearance of pathogens [24] . The task of the adaptive immune system is to ensure the destruction of the invading pathogens with antibodies and cytotoxic T cells. The adaptive immune system recognizes specific molecular structures and is dependent on the generation of large numbers of antigen receptors by the processes of somatic rearrangement [25] .
In order for leukocytes (immune cells) to initiate an immune response they must detect the presence of invading pathogens. The recognition is then followed by destruction and clearance of the pathogens [26] . Innate-based leukocytes sense the surrounding with an array of cellular and intracellular receptors. Among these receptors are the Toll-like family members, peptidoglycan recognition proteins and scavenger receptors [27] . It is the role of these receptors to generate an outside-in signaling cascade that will activate the leukocytes upon recognition of pathogen specific molecules such as lipopolysaccharides, viral DNA, viral RNA and many others [28] . Innate-based leukocytes are also activated in response to the release of intracellular proteins into the cellular matrix [29] , or in response to bioactive peptides that are released by neurons [26] . Upon receptor activation, leukocytes increase production of inflammatory messengers including cytokines, chemokines, prostanoids, leukotrienes, nitric oxide and other reactive oxidants [30] . These messengers stimulate both native and adaptive leukocytes to undergo maturation and differentiation [30] .
Adaptive immune recognition is mediated by two types of antigen receptor: T-cell receptors and B-cell receptors [31] . Unlike Toll-like receptors (TLRs), which are evolutionarily conserved, T-and B-cell receptors are assembled from variable and constant fragments through recombination-activating gene protein-mediated somatic recombination. This process yields a diverse repertoire of receptors [32] . Initiation of the adaptive immune response is dependent on T cells recognizing of foreign peptides bound to self-MHC molecules expressed on antigenpresenting cells [33] . Upon activation, B cells begin to produce specific antibodies for the antigen while T cells are responsible for the destruction of pathogens and infected host cells.
Modulation of the immune response
In most cases there is no need to interfere with the activity of the immune system. A functional immune system can effectively cope with invading pathogens while at the same time prevent damage to host tissue. Nevertheless, there are occasions where the immune system is either incapable of mounting a successful immune response against invading pathogens, or occasions in which the immune system generates an overactive immune response. Regardless of the immune response is over-or under-active, in both cases the end result could be an illness and possibly death.
Insufficient immune responses in healthy individuals can happen when the invading pathogen employs mechanisms that enable it to elude detection by the immune system. Among the many examples are the bacterial infection of Yersinia [34] , or in viral infections such as hepatitis C [35] , human papilloma virus [36] and HIV [37] . Another case of an insufficient immune response is with tumors, where cancer cells evade immune detection and are not destroyed by the immune system [38] .
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Grand challenges in modulating the immune response with RNAi nanomedicines Review An overactive immune response can also lead to tissue damage [26] . Inflammatory responses are self-controlled by anti-inflammatory mediators secreted during the process. The control of an inflammatory response depends on a local balance between promoter and antagonistic inflammatory factors. An insufficient response could compromise the ability of the immune system to fight pathogens, while an excessive response could lead to pathological conditions such as septic shock [39] and organ failure [40] .
Misidentification of host cells as foreign pathogens by the immune system can lead to pathologies such as autoimmune diseases. Autoimmune diseases occur in up to 3-5% of the general population and are classified as an attack of the immune system against self cells and organs [41] . Autoimmune diseases are dependent on the activity of the adaptive immune system, either by the production of auto antibodies against self-epitopes in B cells, or by the recognition of self-epitopes by natural killer cells or cytotoxic T cells [41] . The innate immune system also plays a vital role in autoimmune diseases. Activation of the innate immune system by a TLR agonist promotes cytokine secretion, which in turn substantially elevates immune responses to unrelated antigens by inducing class II MHC and costimulatory proteins such as B7-2 and OX40L [42] . The same cytokines also increase the activity of antigen-presenting cells, thus creating more opportunities for self recognition [43] .
In vivo hurdles of immune modulation with rNAi
RNAi is routinely used in the laboratory to induce targeted gene silencing in cell cultures. Transferring RNAi-based gene silencing from the laboratory bench to whole animal studies has met with great difficulties. In vivo RNAi is hampered by the physiological barriers and by adverse effects to the RNAi treatment [44, 45] .
Successful in vivo RNAi is dependent on the ability of the siRNA to reach the target cells, cross the cellular plasma membrane and escape from the endosomes that often entrap cargo such as nucleic acids. In addition, it is important that no adverse effects such as cytokine induction, lymphocyte activation or a robust interferon response will occur. In order to address these issues two questions have to be asked: how will the siRNA molecules be prepared for the transfection, and how the will the siRNA molecules be administered? The answer to these questions is dependent on the particlular subsets of leukocytes we wish to target. The immune system is composed of many subsets of leukocytes, each with its own characteristics and distinct location in the body. This offers a wide variety of targets for RNAi, each with different challenges and potential solutions. n Challenge 1: stabilizing the siRNA molecules by chemical modification The siRNA molecules are extremely unstable in plasma due to serum nucleases, with a half-life of minutes [46] . This problem can be rectified by chemically modifying the siRNA [47] , or by encapsulating, conjugating, or complexing the siRNA in variety of particulate and soluble delivery systems (Figure 1) [45, 48] .
There are several chemical modifications that can be performed on the siRNA molecules with little loss of gene silencing activity. Chemical modification can be achieved by substitution of sulfur for oxygen forming phosphorothioate oligonucleotides; this is the most common stabilizing modification for both strands of the siRNA molecules. However, phosphorothioate oligonucleotides can bind nonspecifically to proteins, and thus increase the risk of toxicity [49] . Additional chemical modif ications include 2´-O-methyl modifications and locked 
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Molecules such as peptides, polymers, lipids and other small molecules can be attached to the end of the siRNA [52] ; an example is the conjugation of cholesterol to the 5´ of an siRNA molecule. Cholesterol conjugation other than protection from serum nucleases has enabled improved uptake by the liver with robust gene silencing [53] . n Challenge 2: stabilizing the siRNA molecules by encapsulation methods siRNA molecules can be protected from serum nucleases by encapsulation or complexation of naked (or chemically modified) siRNAs to form a nanoparticle that acts as a delivery vehicle. There are many formulations that have been used to transfect siRNA: liposomes [54] , micelles [55] , polymers [56] , microemulsions [57] , proteins [58] , peptides [59] , nanogels [60] and reconstituted virus envelopes [61] , to name a few. Most encapsulations of siRNA in delivery vehicles depend on the electrostatic interactions between the negatively charged nucleic acids and the cationic molecules that protect the RNAi payload from serum nucleases [54] . Encapsulation of the siRNA also improves RNAi activity. The siRNA, with a Mw of ~ 13 kDa and a negatively charged backbone, will not be able to diffuse via the cellular membrane. Delivery vehicles, other than protecting the siRNA from degradation, enable it to enter the cellular membrane more efficiently [62] .
The most common in vitro transfection agents are cationic liposomes [63] . Liposomes are defined as an aqueous compartment enclosed in a phospholipid bilayer [64] . Liposomes can fuse with cellular membranes and deliver their cargo into the cell membrane and thus have been used extensively to deliver small molecule drugs into cells [65] . The lipid composition of the liposomes determines the liposomes specific characteristics and activity. When cationic liposomes interact with negatively charged oligonucleotides they form amorphous particles known as lipoplexes. Lipoplexes will protect oligonucleotides from enzymatic degradation and deliver the siRNA molecules into cells by interacting with the negatively charged cell membrane [66] . Liposomes can be produced in different sizes and have variable surface charges and thus can be used for in vivo delivery [67, 68] .
Other forms of transfection agents are also based on cationic interactions but instead of cationic lipids, cationic polymers are used. Polymers benefit from having a larger versatility than lipids as they can be easily modified by changing the molecular weight or the geometry. They also benefit from having the ability to covalently bind targeting molecules. Polymers can also be fashioned from natural materials such as polysaccharides (chitosan, alginate and cyclodextrins [CDs]) or from synthetic polymers such as polyethyleneimine (PEI).
PEI is an organic molecule with a high cationic charge-density potential based on the presence of multiple amino groups within its backbone. Additionally, PEI is able to retain an important buffering capacity at virtually any cellular pH, thus protecting the siRNA molecule and avoiding lysosomal nuclease degradation [69] . PEI will spontaneously adhere to and condense siRNA to form toroidal complexes that are readily endocytosed by cells. Furthermore, it has been shown that PEI complexes are introduced into the cell by adsorptive endocytosis [70] .
Chitosan (CS) is a linear polysaccharide composed of b-(1,4)-linked d-glucosamine and N-acetyl-d-glucomasine. CS is obtained by deacetylation from chitin, a highly abundant polysaccharide, which is the main component of the exoskeleton of crustaceans [71] . CS-based delivery systems have been described for nasal, ocular, oral, parenternal and transdermal drug delivery. Among the many advantages of CS are its low cytotoxicity and biocompatibility [71] . Despite of these advantages, CS is inherently insoluble in aqueous solutions above pH 6.5 [72] . A high degree of deacetylation, low molecular weight and chemical modification can facilitate water solubility of CS. These factors also affect particle properties such as size, surface charge, drug entrapment efficiency and stability [71] .
A lginate which is a linear anionic polysaccharide composed of alternating blocks of 1,4-linked b-d-mannuronic acid and a-lguluronic acid residues [73] . As a polymer used in drug delivery, alginate possesses several attractive properties; it is biocompatible, nontoxic, water soluble and has the highest mucoadhesive strength in comparison to other natural polysaccharides such as chitosan and carboxymethylcellulose [73] .
CDs are natural cyclic oligomers of a-(1,4) linked-glucopyranosyl that are produced from starch by enzymatic conversion (Figure 2 ). There are three main members of the CD family, composed of six, seven and eight glucose units and known as a-, b-and g-CD, respectively. CDs have a hydrophilic exterior and a hydrophobic cavity Grand challenges in modulating the immune response with RNAi nanomedicines Review that enables them to act as hosts to hydrophobic molecules [74, 75] . CDs are biocompatible, do not elicit an immune response, and have low toxicities in animals and humans [75] . Therefore, they are used in pharmaceutical applications for numerous purposes, including improving the bioavailability of drugs [75] . CD-based therapeutics have been reviewed elsewhere [74, 75] .
Integrin-targeted and -stabilized lipidbased nanoparticles are approximately 80 nm in size and are neutral liposomes loaded with siRNAs precondensed with protamine. Each liposome carries a high payload (~4000 siRNAs per particle) allowing therapeutic efficacy at a low dose (~2.5 mg/kg). The particles are coated with hyaluronan, a naturally occurring glycosaminoglycan that stabilizes siRNA entrapment, inhibits nonspecific reticuloendothelial system uptake in vivo and serves as the attachment site for antibodies [76] .
Targeted siRNA delivery
The ability to target specific cell types provides the dual benefit of reducing the dose required for a therapeutic benefit and minimizing toxicity from uptake into bystander cells. Targeting can be achieved by directly conjugating the siRNA molecule with a small molecule that specifically binds to the cell of interest, or by attaching a targeting molecule such as an antibody to the nanoparticles that encapsulate the siRNA. Alternately, targeting can be achieved by complexing the siRNA with a protein that contains both a targeting peptide and an RNAbinding domain.
siRNAs can be conjugated to small molecules that directly bind to cell surface receptors. This phenomenon was demonstrated with siRNA bound to cholesterol. The cholesterol moiety enhances retention of the conjugated siRNA in the circulation by binding to albumin, lowdensity lipoprotein and high-density lipoprotein particles, as well as uptake in hepatocytes by binding to low-density lipoproteinreceptors and uptake in the liver, gut, kidney and steroidogenic organs by binding to the scavenger receptor class B, type I receptors, which take up highdensity lipoprotein [77] . Another example of this approach is 'siRNA dynamic polyconjugates' [78] . In this intelligently designed delivery system, siRNAs are conjugated to membrane-penetrating polymers, whose activity is unmasked only after reaching the acidic environment of the endosome. Therefore, in principle, cell membrane toxicity by the polymer is limited. The polymers are conjugated to polyethylene glycol (PEG) to reduce nonspecific uptake by phagocytic cells en route to the liver and with N-acetylgalactosamine, which binds to the asialoglycoprotein receptor expressed on hepatocytes, but not other resident cells in the liver.
A variation of conjugated siRNAs are aptamersiRNA chimeras that fuse an siRNA with a structured piece of RNA, called an aptamer, that can be selected to bind with high affinity and specificity to a cell surface ligand. AptamersiRNA chimeras that utilize an aptamer that recognizes prostate surface membrane antigen specifically deliver siRNAs and inhibit tumor outgrowth in a xenograft model of human prostate cancer [79, 80] . Moreover, they are not cytotoxic and do not trigger interferon or inflammatory cytokines. Because of their small Nanoparticles carrying siRNAs have also been used to induce functional silencing in subcutaneously transplanted tumors in nude mice. In one early study, PEI polymers, linked to PEG to enhance circulating half-life and to an RGD (Arg-Gly-Asp) peptide that binds to integrins, can be complexed with siRNAs to form polyplexes that reportedly deliver siRNAs to tumor vasculature and tumor cells that overexpress a v integrins [82] . However, this study did not convincingly show either siRNA delivery or target gene knockdown and did not examine the immune stimulation or toxicity (PEI is known to have significant cytotoxicity). Another polymer based on a CD-containing polycation (CDP) also delivers siRNAs into subcutaneous tumor xenografts in mice [83] . CDP is a polymer with a cyclic oligomeric glucose backbone that assembles into a colloidal 50-70 nm particle when complexed with siRNAs. To achieve targeting, transferrin (Tf )-coupled PEG was attached to the surface of the particles to exploit the upregulation of Tf receptors on cancer cells. However, despite the fact that CDP is less toxic than other cationic polymers (e.g., PEI), injection of CDP nanoparticles into nonhuman primates at the high concentration tested led to elevated blood urea (which might indicate kidney toxicity) and a mild increase in serum liver enzymes and IL-6. Multiple injections of the particles induced antibodies to human Tf. Despite these potential problems, Tf-coupled CDP nanoparticles that contain siRNAs targeting a ribonucleotide reductase subunit gene are being tested in Phase I studies in patients with refractory solid tumors [84] . In a few patients, gene knockdown and siRNA delivery to biopsied melanoma tumors was demonstrated, but no clinical effects have yet been reported [85] .
Another example of targeted liposomes takes advantage of the high expression of the vitamin A-binding receptor, retinol-binding protein, on perisinusoidal hepatic stellate cells to deliver siRNAs specifically to this specialized cell type in the rat liver [86] . Stellate cells play a central role in vitamin A uptake and storage, but are also responsible for liver fibrosis in response to liver injury. They express a heat shock protein (gp46) that acts as a chaperone for collagen and is needed to secrete and deposit extracellular collagen in fibrotic liver. In this study, commercially available lyophilized liposomes composed of cholesterol, dioleoylphosphatidylethanolamine and the cationic lipid O,O´-ditetradecanoyl-N-(atrimethylammonio-acetyl) diethanolamine chloride were reconstituted in water containing retinol and an siRNA targeting gp46. After intravenous injection of these liposomes to rats with fibrotic livers, the incorporated retinol delivers the siRNA payload almost exclusively to hepatic stellate cells and not to other resident liver cells (hepatocytes and Kupffer cells). Rats treated with 0.75 mg/kg gp46 siRNAcontaining vitamin A liposomes two-or threetimes a week show impressive protection from fibrotic liver damage-related death caused by dimethylnitrosamine. Knocking down gp46 reduces collagen secretion and causes stellate cell apoptosis. Importantly, the siRNA treatment also reverses already established fibrosis in this model. In rats without fibrosis there was some uptake in macrophages. It might be worth investigating whether direct conjugation of vitamin A to the siRNA would also work and circumvent the need for liposomes.
An additional liposome startegy has been used to target liposomes to tumors. Liposomes encapsulating Her2 siRNAs with histadinelysine peptides that facilitate endosomal release were targeted to prostate cancer xenografts by incorporating an scFv to the Tf receptor, whose expression is increased on the membranes of tumor cells [87] . n Challenge 3: choosing the appropriate route of administration Choosing the appropriate route of administration of siRNAs is essential for a successful therapeutic Grand challenges in modulating the immune response with RNAi nanomedicines Review effect. There are two main ways of administering siRNA molecules, either by systemic delivery or by local delivery (Figure 1) [88] . Local delivery of siRNA can be performed if the target cells are in the eyes [89] , lungs, nasal cavity [90] , skin [91] , vaginal [92] and rectal cavity [93] . Alternatively, local delivery can be attained by injection of the siRNA molecules directly into the organ, such as by intracerebroventricular injections of siRNA [91] or intratumor injections [81] . Local administration holds several advantages such as low effective dosage, simple formulation and low risk of inducing adverse effects [94] . Systemic administration can be achieved intravenously, intraperitoneally [95] or orally [96] . The siRNA is then delivered into the target cells by the blood circulation.
Although intravenous injection of siRNA is the most common method used in the reported literature, it also poses significantly more challenges (Figure 2) . Even if the siRNA molecules are protected from degeneration by plasma proteins, these molecules still have a long way to reach their target cells. The first challenge is to evade renal clearance; molecules with a molecular weight of less than 50 kDa are susceptible to glomerular filtration and are excreted into the urine [97] . The second challenge is evading the reticuloendothelial system; it is the role of the reticuloendothelial system to clear the body of foreign pathogens, remove cellular debris and clear cells that have undergone apoptosis [98] . Any form of particulate carrier entrapping RNAi payloads that enters the bloodstream is targeted by opsonins, which include immunoglobulins, complement components and other proteins. Opsonized particles are recognized by a variety of receptors present on the cell surface of macrophages that reside in the liver, spleen, bone marrow and other organs [99] . Nanoparticles will usually be taken up depending on their surface characteristics [100] , their size [101] or shape [102] . While in some cases this strategy is used to deliver siRNA to phagocytic cells such as Kupffer cells in the liver [103] or splenic macrophages [96] , in most cases it prevents RNAi payloads from reaching their cellular target. This can be modified as is in the case of PEGylated liposomes that have reduced opsonization rate and thus have improved circulation time [104] .
Regardless of whether the RNAi payloads are administered systemically or locally, in order to affect the cellular target, siRNA molecules must enter the cell cytoplasm and in order to do so the RNAi molecules must first penetrate the tissue extracellular matrix. The extracellular matrix is a dense network of proteins and polysaccharides that can act as a barrier to the transport of macromolecules and nanoparticles [105] . From in vitro studies it is known that many variables can affect siRNA transfection. The transfection of siRNA molecules is dependent not only on the characteristics of the siRNA such as length and charge, but also on the physical characteristics of its carrier: shape, size, chemistry and charge. Additionally, the target cell characteristics such as structure, membrane composition, size and even growth conditions [106] can also affect transfection. Most siRNA delivery vehicles enter by endocytosis and must escape the endosomes and unpack the RNAi cargo in the cytosol, in order to be recognized by the RISC proteins [62] . n Challenge 4: immune response to the siRNA payloads The immune system can respond to invading microbes in several key ways, one of which is the antiviral interferon (IFN) pathway. IFN is a group of cytokines comprising both type 1 and 2 IFN as well as IL-28 and IL-29. Only type 1 IFN, which is composed of several IFN-a and a single IFN-b type, are inducible by viruses directly [107] . Long oligonucleotides are known to trigger type 1 IFN responses in mammals, but it was hoped that short dsRNA, like siRNA, would not be detected by the immune system [108, 109] . However several studies showed that siRNA can produce a robust immune response [110] [111] [112] .
Two mechanisms are known for initiating IFN response. One is exclusive to the immune system and one is present in most mammalian cell types. In the immune system three TLRs are responsible for the detection of foreign RNA molecules, specifically TLR3 [113] , TLR7 [114] and TLR8 [115] . In other cells, dsRNA-dependent PKR, 2´,5´-oligoadenylate synthetase [116] and RIG-I receptors [117] , can produce an IFN response. In nonimmune cells, PKR phosphorylates intracellular targets including the protein synthesis initiation factor elF-2a and blocks the translation of proteins, an essential step in antiviral resistance [118] . IFN response can be minimized by careful planning of the structure and sequence of siRNA molecules. Examples range from removing of the triphosphate group at the 5´ end, which can trigger an IFN response [119] , to excluding sequences such as UGUGU [110] and GUCCUUCAA [120] . Chemical modification
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Nanomedicine ( Review Goldsmith, Mizrahy & Peer such as substitution of all 2´-OH residues on the siRNA with 2´F, 2´O-Me or 2´H residues can also inhibit the activation of an IFN response [121] . Other chemical modifications can also inhibit TLR activation by siRNA molecules [122] .
The immune response is not necessarily initiated by the siRNA molecules. The nanoparticles encapsulating the siRNA can also initiate an immune response. Cationic liposomes are known to induce toxicity when injected in vivo, with effects ranging from blood clotting [123] to immunostimulation [124] . Cationic liposomes use endosomal-mediated cellular membrane entry to facilitate siRNA transfection. As TLRs, RIG-I and PKR receptors are predominantly expressed on the inner membrane of the endosome, cationic liposome-mediated transfection increases the exposure of siRNA to these receptors and thus [154] Cytosolic phospholipase A2a
Collagen-induced arthritis Intravenous Cationic liposomes [155] TAK1 Collagen-induced arthritis Myeloid cells Intravenous Cationic liposomes [156] Fas CLP Intravenous Cationic liposomes [135] IL-6 BD Intraperitoneal Cationic liposomes [136] IL-18, IL-6, IL-1 Collagen-induced arthritis Intravenous Cationic liposomes [157] TNF-a HSV-induced inflammation Intraperitoneal Cationic liposomes [130] TLR4 Nonseptic thermal injury Leukocytes Intravenous Cationic liposomes [158] TNF-a LPS-induced inflammation Rat Kupffer cells Intravenous Liposome encapsulated [103] TREM-1 Sepsis Hydrodynamic delivery Naked siRNA [137] Ikkb Renal ischemia-reperfusion Renal artery injection Chemically synthesized siRNA [159] TNF-a Collagen-induced arthritis Knee joint injection, followed by electroporation Naked siRNA? [140] 
Cd40
Humoral acute rejection B and T cells Infusion electroporation Chemically synthesized siRNA [139] K17 SCID-hu xenogeneic transplantation model for psoriasis Topically Emulsion vehicle [141] STAT6 Allergic airway disease Intranasal Naked or cholesterolconjugated siRNA [142] EGFP Pulmonary siRNA delivery Mouth and trachea intubation PEI copolymers [143] PUMA, BIM CLP T and B cells Retro-orbital venous plexus injections Cyclodextrin polymer based [146] TNF-a Arthritic model Macrophages Intraperitoneal Chitosan/siRNA nanoparticles [144] 
Map4k4
LPS lethality test Macrophages Oral delivery GeRPs [96] TNF-a Macrophages Intraperitoneal PLA biodegradable microspheres [145] TNF-a LPS-induced neuronal cell death Macrophages Intravenous RVG peptides -conjugated to 9R [147] 
Stat3
Tumor model Intratumor/intravenous Chemically attached CpG oligonucleotides [148] Cyclin D1 Colitis Lymphocytes Intravenous Integrin b7-targeted and -stabilized liposomes [149] CCR5 HIV infection experiments Lymphocytes Intravenous Integrin LFA-1-targeted and -stabilized liposomes Grand challenges in modulating the immune response with RNAi nanomedicines Review elevate the IFN-1 response [125] . . The cationic lipids also initiate the immune response with the direct activation of TLR4 [126] . n Challenge 5: comprehensive manipulation of the immune response in vivo Despite all of the obstacles that face successful in vivo RNAi, several groups have demonstrated that the immune response can be modified with siRNA. Generally, in vivo immune response modification can be divided into two categories: inhibition of the immune response or enhancement of the immune response. Inhibition of the immune response was demonstrated by several groups (Table 1) . Inhibition of the immune response was accomplished in several approaches ranging from downregulation of cellular receptors in order to prevent cell activation [127, 128] to downregulation of transcription factors that are essential for immune activity [16] [17] [18] or to the common method of downregulation of proinflammatory cytokine production [16, 17] , with TNF-a being the most inhibited cytokine [103, [129] [130] [131] . A different approach is to inhibit genes in nonimmune cells to protect them from damage caused by an immune response [132] .
Inhibition of the immune response can be divided into two types: inhibition of a general systemic inflammatory process or targeting of a specific immune cell type. The preparation of the siRNA, its vehicle and the method of administration are dependent on the type of immune process and type of immune cells.
It is not surprising that when trying to affect a general systemic inflammatory process the most common method of transfection is nontargeted cationic formulation (usually based on liposomes). Despite there known toxicological properties, cationic liposomes successfully moved from the laboratory bench to in vivo experiments such as sepsis and arthritis modules [133] [134] [135] [136] . Cationic liposomes have also been used to target specific cells such as B cells in the systemic lupus erythematosus murine model [128] . Inhibition of a general multicell inflammatory process can also be accomplished without the use of a carrier for the siRNA. Naked siRNA [137] and chemically modified siRNA [138] were used to inhibit sepsis in mice. It should be noted that the naked siRNA was administered using the hydrodynamic delivery method, which is impractical for human treatment [137] . Interestingly, chemically modified and naked siRNA are also used with electroporation. Inhibition of CD40 in transplanted kidneys via electroporation reduced graft-versus-host reaction [139] . Moreover, collagen-induced arthritis was inhibited by naked siRNA and electrophoresis [140] .
As discussed earlier in this review, local siRNA treatment offers great advantages over systemic administration but at the same time presents a greater challenge. There are two distinct approaches that were successfully used in order to locally inhibit an immune response: local delivery method, which is nonselective, and cellular targeting to specific cell types.
Local delivery methods range from topical treatment [141] to intranasal [142] , trachea intubation [143] and intraperitoneal injections [130, 136, 144, 145] . Intestingly, in contrast to systemic injection where nontargeting cationic carriers were the predominant vehicles, local treatments have a much broader range of vehicles that are tailored to the specific administration method. Topical treatment was achieved with an emulsion vehicle [141] , intranasal treatment was preformed with naked or cholesterol-conjugated siRNA [142] and trachea intubation was preformed with a PEI copolymer [143] . Intraperitoneal treatments Table 2 . Inhibition of viral genes using rNAi.
Animal model
Target gene route of administration delivery system ref.
Viral infection RSV targets
Intranasally siRNA [160] Hepatitis B HBx Intravenous Cationic liposomes [161] Ebola virus in mice and nonhuman primate
Ebola targets Bolus intravenous infusion
Cationic liposomes [162] West Nile virus WNV targets Intravenous RVG-9R peptides [163] HIV in humanized mice VIF Intravenous scFvCD7-9R [164] HBV HBV targets Hydrodynamic shRNA [19] HIV in humanized mice CD4, CCR5 Intravenous Integrin LFA-1-targeted and -stabilized liposomes [150] Respiratory viral infection RSV targets Nasally administered TransIT-TKO [165] LFA-1: Lymphocyte function-associated antigen 1.
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Review Goldsmith, Mizrahy & Peer included the use of cationic liposomes [130, 136] but also employed vehicles such as a PEI copolymer [143] a CD polymer [146] , chitosan/ siRNA nanoparticles [144] and poly(d,l-lactide) biodegradable microspheres [145] . An interesting approach for targeting siRNA was encapsulation of the siRNA in b1,3-d-glucan particles, which are derived from baker yeast [96] . Selective cellular targeting can be achieved by attaching a targeting moiety (be it an antibody or its fragment, a natural ligand or an aptamer) to the nanoparticle surface that encapsulate the siRNA payload, or directly to the siRNA molecule. Examples of immune modulation with targeted siRNA ranged from direct binding to the siRNA molecules such as in the case of RVG peptide [147] or CpG oligonucleotide [148] to the binding of antibodies to the siRNA vehicle [149] [150] [151] .
It is no surprise that RNAi can be used to assist and augment the immune response as the origin of endogenous RNAi is thought to be a mechanism against viral attacks [6] . Several groups have shown that siRNA can downregulate specific viral genes (Table 2 ) and when a general systemic antiviral effect was required, intravenous injections were the desired method. It should be noted that there are some concerns about using RNAi to inhibit viral infections and tumor growth. As mentioned earlier, siRNA and its nanocarriers can elicit an IFN immune response; such a response could affect viral infection and tumor growth. Several studies have shown that the antiviral [152] and antitumor [114] effect of RNAi treatment is not dependent only on the inhibitory effect of siRNA, but also on the immunostimulatory effect of the RNAi treatment. Specific siRNA has been produced to combine immune response and antitumor gene silencing to destroy tumors [153] .
Future perspective
Gene silencing by RNAi has the potential to provide therapeutic treatment for disorders of the immune system. In the past few years, great leaps have been made in improving and refining oligonucleotide delivery, yet in vivo RNAi is still hampered by physical and biological hurdles. Despite these obstacles, several groups have successfully managed to modulate key processes of the immune response proving that RNAi can be used as a therapeutic technique in treating immune system-based disorders. With the progression in RNAi delivery and specifically targeted delivery, the capability to modulate the immune response will grow and perhaps immune response modulation will become a standard treatment for leukocyte-implicated diseases such as blood cancer, inflammation and viral infection. 
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executive summary
Gene silencing by RNAi, the sequence-specific natral phenomena, has the potential to change the therapeutic space in many dieseases in general, and in leukocyte-implicated diseases such a blood cancer, inflammation and viral infection, in particular. Great leaps have been made in improving and refining RNAi delivery startegies using different nanoparticles to create RNAi nanomedicines. Yet, in vivo RNAi is still hampered by physical and biological hurdles. Despite these challenges, several groups have successfully managed to modulate key processes of the immune response proving that RNAi can be used as a therapeutic technique in treating immune system-based disorders. With the progression in RNAi delivery and specifically targeted delivery, the capability to modulate the immune response will grow and perhaps immune response modulation will become a standard treatment for leukocyte-implicated diseases. The five major challenges in the context of nanomedicines are: -Stabilizing the siRNA molecules by chemical modification -Stabilizing the siRNA molecules by encapsulation methods -Choosing the appropriate route of administration of the RNAi nanomedicines -Immune response to the siRNA payloads -In vivo manipulation of the immune response Despite these challenges, the potential to utilize RNAi nanomedicines for the discovery of new therapeutic targets in leukocyte diseases and also to create a novel therapeutic modality to treat many types of inflammatory disorders and cancer is enormous. 
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